Keros Therapeutics (NASDAQ:KROS) Earns “Neutral” Rating from Guggenheim

Guggenheim reiterated their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note published on Friday morning,Benzinga reports.

KROS has been the topic of a number of other reports. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Scotiabank lowered their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $10.86 on Friday. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $73.00. The stock has a market capitalization of $439.91 million, a PE ratio of -2.08 and a beta of 1.43. The business’s 50-day moving average is $37.51 and its 200 day moving average is $47.36.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the company posted ($1.33) EPS. The business’s revenue was up 4750.0% on a year-over-year basis. As a group, equities research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Trading of Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KROS. KBC Group NV boosted its stake in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics in the 2nd quarter worth about $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics in the 3rd quarter worth about $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.